Hansa Biopharma — November 2025

[Henrikhot]

Ryk tre felter tilbage…..du er landet på Rådhuspladsen. Er det tid til refill?

[LP90]

Fatter ikke den her case fin emission på 672 Mill til kurs 39,5 for 5 uger siden og Jefferies kursmål på 100 for 3 uger siden og vi er handlet ned i kurs 26 og der har været et fint insiderkøb og alligevel er short steget fra ca. 3,7 til 5 % hvad ser de som ikke er oplyst nogen der har de visse ord ???

[exitnu]

LP90 - bare hold fast!

[exitnu]

Hansa Biopharma AB: Kommande KOL-samtal idag: Insikter om klinisk praxis och fas 3- resultaten med imlifidase

Eventet finder sted i dag, onsdag den 12. november 2025 kl. 15.00.

Link til det virtuelle møde: https://lifescievents.com/event/gl39mp2j/

[exitnu]

Upcoming KOL Call today: Insights on clinical practice and imlifidase Phase 3 Results

https://www.hansabiopharma.com/media/press-releases/2025/upcoming-kol-call-today-insights-on-clinical-practice-and-imlifidase-phase-3-results/

[LP90]

exitnu det gør jeg også har så mange at jeg vil slå bunden ud af min økonomi hvis jeg skulle tage det kæmpe tab

[exitnu]

Før daggry er mørket stærkest, godt du holder ved

[exitnu]

Hansa Biopharma: Notes on KOL Comments on ConfideS

https://www.redeye.se/research/1138601/hansa-biopharma-notes-on-kol-comments-on-confides

[exitnu]

"In summary, we think the KOL event underlines the high unmet need that imlifidase satisfies and gives us stronger conviction in our sales forecast. We believe the market does not fully appreciate the high likelihood of approval (barring any CRL) and likely rapid uptake of imlifidase in the US, basing its expectations on the relatively unsuccessful European sales trajectory."

[collersteen]

"relatively unsuccessful" er vist en meget pæn formulering

[exitnu]

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Hansa Biopharma AB, retaining the price target of SEK132.00.

[exitnu]

Optimistic Buy Rating for Hansa Biopharma AB: Imlifidase’s Potential in Kidney Transplantation Highlighted by Key Opinion Leaders

https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-hansa-biopharma-ab-imlifidases-potential-in-kidney-transplantation-highlighted-by-key-opinion-leaders-ratings

[Henrikhot]

Highly sensitized kidney patients (PRA >85%) face extremely low chances of receiving a compatible donor organ, even within priority programs like Eurotransplant’s Acceptable Mismatch system.

[Henrikhot]

New Belgian consensus guidelines outline when and how to use imlifidase for desensitization, offering a realistic pathway to transplantation for patients who would otherwise remain on dialysis for years—or never be transplanted at all.

[Henrikhot]

https://journals.lww.com/transplantjournal/fulltext/2025/08000/belgian_consensus_guidelines_within_eurotransplant.6.aspx

[Henrikhot]

Shortede aktier i Hansa B. https://shortregister.com/se/hansa-biopharma-hnsa?utm_source=chatgpt.com

[Henrikhot]

5,12 % af aktierne er shortede. Den bliver dyr, når de skal ud af den samtidig.

[Cupcake]

26/11 Leerink Partners Initiates Coverage of Hansa Biopharma with Outperform Rating, Target Price Set at SEK 102 - BN
https://www.marketscreener.com/news/leerink-partners-initiates-coverage-of-hansa-biopharma-with-outperform-rating-target-price-set-at-s-ce7d5ed2d180f020

[LP90]

Godmorgen endnu et fint kursmål langt over dagens kurs det har vi set tit men det hjælper ikke en skid kursen hænger fast her nede i intervallet 25-40 det har den kørt i de sidste
14 mdr.